FDA Accepts Evoke Pharma's NDA Resubmission for Gimoti(TM)

Stock Information for Evoke Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Evoke Pharma Inc.

Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
Evoke Pharma Announces Closing of $7.5 Million Public Offering
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.